Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients.